948571-47-9

Basic information

• Product Name: 2-(4-AMino-1H-pyrazol-1-yl)ethanol
• Synonyms: 2-(4-Amino-1H-pyrazol-1-yl)
• CAS NO: 948571-47-9
• Molecular Formula: C₅H₉N₃O
• Molecular Weight: 127.14446
• Mol File: 948571-47-9.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 337.9±22.0 °C(Predicted)
• Appearance: /
• Density: 1.35±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 14.42±0.10(Predicted)
• CAS DataBase Reference: 2-(4-AMino-1H-pyrazol-1-yl)ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-AMino-1H-pyrazol-1-yl)ethanol(948571-47-9)
• EPA Substance Registry System: 2-(4-AMino-1H-pyrazol-1-yl)ethanol(948571-47-9)

Safety Data

• Hazardous Substances Data: 948571-47-9(Hazardous Substances Data)

Usage

General Description

2-(4-Amino-1H-pyrazol-1-yl)ethanol is a chemical compound that belongs to the class of ethanolamines. It is a derivative of pyrazole, a heterocyclic organic compound. This chemical has a molecular formula C4H7N3O, with the structural formula CH3CHOHCH2NHCH2NH2. 2-(4-Amino-1H-pyrazol-1-yl)ethanol has been studied for its potential pharmaceutical applications, such as its ability to act as an anticonvulsant and its potential use in the treatment of neurological disorders. It is also used in chemical research and as a reagent in organic synthesis. However, the compound may pose hazards to human health and the environment, and proper safety precautions must be taken when handling it.

Upstream product

• 2075-46-9 4-nitro-1H-pyrazole 
• 540-51-2 2-bromoethanol 
• 42027-81-6 1-β-hysroxyethyl-4-nitropyrazole 

Downstream Products

• 1403894-06-3 2-(4-(7-(2-fluorobenzyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-1H-pyrazol-1-yl)ethanol 
• 1429297-41-5 C₂₀H₁₉Cl₂FN₄O₄ 
• 1421856-75-8 C₂₂H₂₁F₂N₇O₃ 
• 1394162-42-5 N-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-5-(m-tolyl)oxazole-4-carboxamide 
• 1394161-75-1 5-m-tolyl-oxazole-4-carboxylic acid {1-[2-(4,6-dimethoxy-pyrimidin-2-yloxy)-ethyl]-1H-pyrazol-4-yl}-amide 
• 1394161-09-1 5-m-tolyl-oxazole-4-carboxylic acid {1-[2-(benzo[1,3]dioxol-5-yloxy)-ethyl]-1H-pyrazol-4-yl}-amide 
• 1394162-45-8 2-(4-(5-(m-tolyl)oxazole-4-carboxamido)-1H-pyrazol-1-yl)ethyl 4-methyl-benzenesulfonate 
• 1394162-44-7 2-(4-(5-(m-tolyl)oxazole-4-carboxamido)-1H-pyrazol-1-yl)ethyl methanesulfonate 
• 1453212-89-9 tert-butyl 4-{2-[4-({5-[(2,6-difluoro-3,5-dimethoxybenzyl)oxy]pyrimidin-2-yl}amino)-1H-pyrazol-1-yl]ethyl}piperazine-1-carboxylate 
• 1453212-32-2 2-[4-({5-[(2,6-difluoro-3,5-dimethoxybenzyl)oxy]pyrimidin-2-yl}amino)-1H-pyrazol-1-yl]ethyl methanesulfonate 

Relevant articles and documents

FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF

The present disclosure relates to a class of fused pyrimidine compounds of Formula I, their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to a process of preparation of these fused pyrimidine compounds, and to pharmaceutical compositions containing them.

Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis

Selective JAK3 inhibitors have been shown to have a potential benefit in the treatment of autoimmune disorders. Here we report the identification of a series of pyrazolopyrimidine derivatives as potent JAK3 inhibitors that exploit a unique cysteine (Cys909) residue in JAK3. Most of these compounds (13k, 13n and 13 t), displayed stronger anti-JAK3 kinase activity and selectivity than tofacitinib. Furthermore, the most active inhibitor 13t (IC50 = 0.1 nM), also exhibited favourable selectivity for JAK3 in a panel of 9 kinases which contain the same cysteine. In a series of cytokinestimulated cellular analysis, compound 13 t, could potently block the JAK3-STAT signaling pathway. Further biological studies, including cellular antiproliferative activity assays and a rat adjuvant-induced arthritis model for in vivo evaluation, also indicated its efficacy and low toxicity in the treatment of rheumatoid arthritis. The results of these experimental explorations suggested that 13t is a promising lead compound for the development of selective JAK3 inhibitor with therapeutic potential in rheumatoid arthritis.

Preparation and application of novel 4,6-disubstituted aminopyrimidine JAK (janus kinase) inhibitor

The invention discloses preparation and application of novel 4,6-disubstituted aminopyrimidine JAK (janus kinase) inhibitors, and provide drugs which can be used for preventing, treating and/or improving autoimmune diseases (for example, psoriasis, rheumatoid arthritis, inflammatory enteritis diseases, Jagren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), and have excellent JAK inhibitory activity. The invention also provides pharmaceutically acceptable composition containing the compounds and methods for preparing the compounds.